Arrowhead Pharmaceuticals, Inc.(ARWR)

$87.90—

Chart

Arrowhead Pharmaceuticals, Inc.(ARWR)

NASDAQ

$87.90—

Chart Studio

ARWR(ARWR)

ARWR

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-1.52

Nov 24, 2026 · Reports after close

Revenue Estimate

$72M

FY2030E EPS$4.41

Analyst Sentiment

Wall St. Consensus

Buy

22 analysts·High coverage

Score

16 Buy (73%)6 Hold (27%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1673%

Hold

627%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$46.00

-47.7%

Consensus

$117.50

+33.7%

Bull

$126.00

+43.3%

12-Month Target Range22 analysts

$46.00$117.50$126.00

Current $87.90Consensus

Current Price

$87.90

Upside to Consensus

$29.60

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-28.20%

EPS—

FY2028

Rev+122.42%

EPS—

FY2029

Rev+50.53%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$477M	$343M	$762M	$1.15B	$2.04B
Low	$389M	$127M	$372M	$716M	$1.28B
High	$646M	$619M	$1.22B	$1.79B	$3.18B
EBITDA Avg	$-301M	$-216M	$-481M	$-725M	$-1.29B
Low	$-408M	$-391M	$-773M	$-1.13B	$-2.01B
High	$-246M	$-80M	$-235M	$-452M	$-805M
EBIT Avg	$-317M	$-228M	$-506M	$-762M	$-1.36B
Low	$-429M	$-412M	$-814M	$-1.19B	$-2.11B
High	$-258M	$-85M	$-247M	$-476M	$-847M
Net Income Avg	$-545M	$-681M	$-440M	$-98M	$589M
Low	$-573M	$-994M	$-664M	$-170M	$301M
High	$-280M	$-300M	$89M	$-50M	$1.02B
EPS Avg	$-3.51	$-4.72	$-2.50	$-0.74	$4.41
Low	$-4.28	$-7.43	$-4.97	$-1.27	$2.25
High	$-2.09	$-2.24	$0.67	$-0.38	$7.59
Analysts (Rev / EPS)	9 / 10	10 / 11	8 / 7	4 / 2	4 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027
Revenue Avg	$72M	$37M	$40M	$36M	$138M
Low	$5M	$25M	$11M	$10M	$39M
High	$129M	$49M	$76M	$69M	$266M
EBITDA Avg	$-45M	$-23M	$-25M	$-23M	$-87M
Low	$-81M	$-31M	$-48M	$-43M	$-168M
High	$-3M	$-16M	$-7M	$-6M	$-25M
EBIT Avg	$-48M	$-24M	$-26M	$-24M	$-92M
Low	$-86M	$-32M	$-50M	$-46M	$-176M
High	$-4M	$-16M	$-7M	$-7M	$-26M
Net Income Avg	$-219M	$-202M	$-200M	$-207M	$-122M
Low	$-283M	$-219M	$-439M	$-454M	$-268M
High	$-149M	$-186M	$-13M	$-14M	$-8M
EPS Avg	$-1.52	$-1.41	$-1.40	$-1.44	$-0.85
Low	$-1.97	$-1.52	$-3.06	$-3.17	$-1.87
High	$-1.04	$-1.30	$-0.09	$-0.10	$-0.06
Analysts (Rev / EPS)	9 / 9	3 / 3	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Aug 6, 2026H.C. Wainwright

Arrowhead price target raised to $120 from $115 at H.C. Wainwright

Target:$120.00

+40.2%from $85.61

Aug 5, 2026Stifel Nicolaus

Arrowhead price target raised to $104 from $98 at Stifel

Target:$104.00

+16.1%from $89.59

Jul 27, 2026H.C. Wainwright

Arrowhead price target raised to $115 from $100 at H.C. Wainwright

Target:$115.00

+34.3%from $85.60

Jul 23, 2026Morgan Stanley

Arrowhead price target raised to $120 from $100 at Morgan Stanley

Target:$120.00

+35.8%from $88.38

Jul 23, 2026Piper Sandler

Arrowhead price target raised to $126 from $110 at Piper Sandler

Target:$126.00

+42.1%from $88.70

Jul 22, 2026Chardan Capital

Arrowhead price target raised to $115 from $90 at Chardan

Target:$115.00

+26.3%from $91.03

Jul 13, 2026Stifel Nicolaus

Arrowhead initiated with a Buy at Stifel

Target:$98.00

+32.2%from $74.11

May 13, 2026Bernstein

Arrowhead price target raised to $46 from $35 at Bernstein

Target:$46.00

-41.8%from $79.04

May 8, 2026Chardan Capital

Arrowhead price target raised to $90 from $80 at Chardan

Target:$90.00

+15.5%from $77.95

Apr 21, 2026Morgan Stanley

Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley

Target:$100.00

+44.4%from $69.25

Feb 6, 2026Morgan Stanley

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Target:$78.00

+17.1%from $66.64

Jan 27, 2026Robert W. Baird

Morgan Stanley on Arrowhead Pharma (ARWR): 'we are encouraged by the on track progress for the ARO-DIMER-PA program'

Target:$81.00

+20.9%from $67.02

Jan 21, 2026H.C. Wainwright

Arrowhead price target raised to $100 from $85 at H.C. Wainwright

Target:$100.00

+45.3%from $68.80

Jan 13, 2026UBS

'Arrowhead Pharma (ARWR) Raises $930 Million to Launch Redemplo'; PT Raised at Piper Sandler

Target:$110.00

+61.7%from $68.03

Jan 13, 2026Piper Sandler

Arrowhead price target raised to $110 from $100 at Piper Sandler

Target:$110.00

+66.8%from $65.93

Jan 7, 2026Morgan Stanley

Arrowhead price target raised to $81 from $48 at Morgan Stanley

Target:$81.00

+14.4%from $70.81

Jan 7, 2026Chardan Capital

Arrowhead price target raised to $80 from $60 at Chardan

Target:$80.00

+13.0%from $70.81

Jan 2, 2026Tudor Pickering

Arrowhead Pharma (ARWR) PT Raised at Bernstein Ahead of Obesity Data Update

Target:$35.00

-47.3%from $66.39

Dec 31, 2025Bernstein

Arrowhead price target raised to $35 from $17 at Bernstein

Target:$35.00

-48.0%from $67.25

Dec 17, 2025Piper Sandler

Arrowhead price target raised to $100 from $70 at Piper Sandler

Target:$100.00

+54.7%from $64.66

Dec 11, 2025RBC Capital

Arrowhead price target raised to $80 from $52 at RBC Capital

Target:$80.00

+16.1%from $68.91

Dec 2, 2025H.C. Wainwright

Arrowhead price target raised to $85 from $80 at H.C. Wainwright

Target:$85.00

+51.1%from $56.25

Nov 26, 2025Morgan Stanley

Arrowhead price target raised to $48 from $45 at Morgan Stanley

Target:$48.00

+2.6%from $46.79

Nov 29, 2024Bernstein

Arrowhead Pharma (ARWR) PT Lowered to $24 at Bernstein SocGen Group

Target:$24.00

-7.0%from $25.81

Nov 27, 2024Loop Capital Markets

Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)

Target:$60.00

+365.1%from $12.90

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance